July 2019

Contents

Editorial

• HTB 24 July 2019 online: first reports from IAS 2019

• HTB 17 July 2019 online: IAS 2019, HIV pipeline, gene-cure mice…

Special reports

• Fit for purpose 2019 – PDF

• HIV pipeline report 2019

Conference reports

• 10th IAS Conference on HIV Science (IAS 2019) in Mexico City

• Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

• WHO recommends dolutegravir-based ART regimens for all

• High rates of viral suppression with low dose efavirenz in pregnant Zambian women

• First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10

• Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results

• Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy

• Fostemsavir: 96-week follow-up in people with multi-drug resistance

• Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96

• Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study

• Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year

• Upcoming 10th IAS Conference on HIV Science (IAS 2019)

• IAS 2019: late breaker highlights to look for

Antiretrovirals

• Dolutegravir/lamivudine approved as dual HIV combination in EU

Guidelines

• IAS–USA update of drug resistance mutations (2019)

Cure-related research

• HIV risk to partners of people in studies with a treatment interruption

• Gene editing to eliminate HIV from mice: misleading and wrongly reported in media coverage

Other news

• UNAIDS call on 48 countries and territories to remove all HIV-related travel restrictions

PDFs

• 24 July 2019 vol 20 no 9

• 17 July 2019 vol 20 no 8